Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $100,000 | 1 | 99.6% |
| Education | $193.62 | 6 | 0.2% |
| Food and Beverage | $167.03 | 6 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Valeant Pharmaceuticals North America LLC | $100,000 | 1 | $0 (2017) |
| Novo Nordisk Inc | $193.62 | 6 | $0 (2023) |
| Insulet Corporation | $103.82 | 5 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.21 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $118.39 | 4 | Novo Nordisk Inc ($96.81) |
| 2022 | $42.41 | 2 | Insulet Corporation ($42.41) |
| 2021 | $114.10 | 4 | Novo Nordisk Inc ($96.81) |
| 2020 | $22.54 | 1 | Insulet Corporation ($22.54) |
| 2018 | $63.21 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($63.21) |
| 2017 | $100,000 | 1 | Valeant Pharmaceuticals North America LLC ($100,000) |
All Payment Transactions
13 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/29/2023 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: Insulin Pump | ||||||
| 01/19/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/19/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 01/19/2023 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
| 08/11/2022 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $17.47 | General |
| Category: Insulin Pump | ||||||
| 07/22/2022 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $24.94 | General |
| Category: Insulin Pump | ||||||
| 07/27/2021 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $17.29 | General |
| Category: Insulin Pump | ||||||
| 02/23/2021 | Novo Nordisk Inc | Victoza (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Diabetes | ||||||
| 02/23/2021 | Novo Nordisk Inc | Victoza (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Diabetes | ||||||
| 02/23/2021 | Novo Nordisk Inc | Victoza (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Diabetes | ||||||
| 06/22/2020 | Insulet Corporation | Omnipod (Device) | Food and Beverage | Cash or cash equivalent | $22.54 | General |
| Category: Insulin Pump | ||||||
| 06/04/2018 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $63.21 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/08/2017 | Valeant Pharmaceuticals North America LLC | RIFAXIMIN (Drug) | — | Cash or cash equivalent | $99,999.50 | Research |
| Study: IISRIF1116Mathur • Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IISRIF1116Mathur | Valeant Pharmaceuticals North America LLC | $100,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 49 | 70 | $22,564 | $4,964 |
| 2022 | 2 | 70 | 165 | $35,525 | $8,672 |
| 2021 | 1 | 49 | 70 | $20,400 | $5,650 |
| 2020 | 2 | 48 | 65 | $16,060 | $3,858 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 70 | $22,564 | $4,964 | 22.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 77 | $24,696 | $5,750 | 23.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 15 | 88 | $10,829 | $2,922 | 27.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 49 | 70 | $20,400 | $5,650 | 27.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 37 | 53 | $13,568 | $3,029 | 22.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 12 | $2,492 | $828.95 | 33.3% |
About Dr. Ruchi Mathur, M.D
Dr. Ruchi Mathur, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184650749.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruchi Mathur, M.D has received a total of $100,360 in payments from pharmaceutical and medical device companies, with $118.39 received in 2023. These payments were reported across 13 transactions from 4 companies. The most common payment nature is "" ($100,000).
As a Medicare-enrolled provider, Mathur has provided services to 216 Medicare beneficiaries, totaling 370 services with total Medicare billing of $23,144. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Los Angeles, CA
- Active Since 06/24/2006
- Last Updated 09/13/2013
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1184650749
Products in Payments
- RIFAXIMIN (Drug) $100,000
- Omnipod (Device) $103.82
- Victoza (Drug) $96.81
- XIFAXAN (Drug) $63.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Los Angeles
Stanley Hsia, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $643,948
Dr. Anthony Heaney, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $466,627
Dr. Shlomo Melmed, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $270,411
Dr. Glenn Braunstein, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $135,158
Laurence Katznelson, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $102,358
Dr. Joseph Kim, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $62,907